跳轉至內容
Merck
  • [Experience in the pre-hospital treatment of acute coronary syndrome with metoprolol succinate].

[Experience in the pre-hospital treatment of acute coronary syndrome with metoprolol succinate].

Klinicheskaia meditsina (2013-06-26)
A L Vertkin, S N Morozov, A I Fedorov
摘要

Patients with acute coronary syndrome and elevated ST segment in the pre-hospital phase were treated with metoprolol succinate (MS) and thrombolytic therapy. Severe and moderate pain decreased by 54.1 and 16.1% respectively within 60 min after MS intake. Systolic (SAP) and diastolic (DAP) arterial pressure dropped by 35.7 and 16.8 mmHg during the same period. The heart rate (HR) decreased by 25.1 beats/min. 21.8 and 25.3% of the patients showed positive dynamics of ST segment 90 and 180 min after intake of MS. The height of the ST segment was normal in 18.4 and 31.0% of the patients respectively. No cases of external heart rupture were documented at autopsy whereas it was a cause of death in 39.1% of the patients given standard thrombolytic therapy. It is concluded that the use of MS starting from the pre-hospital stage in patients with acute coronary syndrome decreases pain intensity. HR, DAP and SAP and helps to prevent heart rupture.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
美托洛尔 (+)-酒石酸盐, ≥98% (titration), powder
Supelco
美托洛尔 酒石酸酯 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
美托洛尔 (+)-酒石酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
美托洛尔 (+)-酒石酸盐, European Pharmacopoeia (EP) Reference Standard